Molecular imaging and therapeutic efficacy of 188Re-(DXR)-liposome-BBN in AR42J pancreatic tumor-bearing mice.

Abstract

Liposomes are good candidates as drug carriers and have been widely investigated in drug delivery systems. In this study, a new combination of bimodal 188Re-(DXR)-liposome-BBN radiochemotherapeutics was designed and studied for treating solid pancreatic tumor by intravenous administration. The in vivo nuclear microSPECT/CT imaging of tumor targeting, prolonged survival time and therapeutic efficacy were evaluated in AR42J malignant pancreatic solid tumor-bearing nude mice. MicroSPECT/CT imaging of 188Re-liposome-BBN pointed to significant targeting in tumors at 24 h after intravenous injection (SUV=2.13 ± 0.98). Co-injection of a blocking dose of cold BBN (4 mg/kg) inhibited the accumulation of 188Re-liposome-BBN in tumors (SUV=1.82 ± 0.31). For therapeutic efficacy, inhibition of tumor growth in mice treated with 188Re-DXR-liposome-BBN was precisely controlled [mean growth inhibition rate (MGI) = 0.092] and had longer survival time [life-span (LS) = 86.96%] than those treated with anticancer drug 188Re-liposome-BBN (MGI = 0.130; LS = 75%), Lipo-Dox-BBN (MGI = 0.666; LS = 3.61%) and untreated control mice. An additive tumor regression effect was observed (CI 0.946) for co-delivery of 188Re-DXR-liposome-BBN radiochemotherapeutics. These results point to the potential benefit of the 188Re-(DXR)-liposome-BBN radiochemotherapeutics for adjuvant cancer treatment with applications in oncology.

• Authors: Ya-Jen Chang, Chia-Yu Yu, Chin-Wei Hsu, Wan-Chi Lee, Su-Jung Chen, Chih-Hsien Chang, Te-Wei Lee
• Journal: Oncology reports (Oncol Rep) Vol. 28 Issue 5 Pg. 1736-42 (Nov 2012) ISSN: 1791-2431 [Electronic] Greece
• PMID: 22922965 (Publication Type: Journal Article)

Chemical References

• Organometallic Compounds
• Radiopharmaceuticals
• Rhenium
• Doxorubicin
• Bombesin

Topics

• Administration, Intravenous
• Animals
• Bombesin (pharmacology, therapeutic use)
• Cell Line, Tumor
• Chemoradiotherapy
• Doxorubicin (pharmacology, therapeutic use)
• Humans
• Mice
• Multimodal Imaging
• Organometallic Compounds (pharmacology, therapeutic use)
• Pancreatic Neoplasms (mortality, therapy)
• Positron-Emission Tomography
• Radiopharmaceuticals (pharmacology, therapeutic use)
• Rhenium (chemistry, pharmacology, therapeutic use)
• Tissue Distribution
• Tomography, X-Ray Computed
• Xenograft Model Antitumor Assays